Does adjuvant vaccine therapy really have activity in malignant melanoma?
暂无分享,去创建一个
[1] J. Schlom,et al. Cancer Vaccines: Moving Beyond Current Paradigms , 2007, Clinical Cancer Research.
[2] J. Kirkwood,et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials , 2007 .
[3] R. Elashoff,et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites , 2007 .
[4] M. Atkins,et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Gore,et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Gore,et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.
[7] J. Abrams,et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] R. Simes,et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Sondak,et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] V. Sondak,et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Darrah,et al. Therapy of Melanoma with Allogeneic Melanoma Lysates Alone or with Interferon-Alfa , 2002, Cancer investigation.
[12] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.
[13] D. Linch,et al. Interferon alfa-2a. , 1997, British journal of hospital medicine.
[14] S. Groshen,et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Groshen,et al. Association of HLA phenotype with response to active specific immunotherapy of melanoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Grunberg,et al. Immunological effects of recombinant interferon-alpha 2 in cancer patients. , 1983, Journal of biological response modifiers.